Loading stock data…
TGTX
$33.85+0.07 (+0.21%)
Market ClosedLast close May 1
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
TG Therapeutics, Inc. in the Healthcare sector is trading at $33.85. The stock is currently 17% below its 52-week high of $40.99, remaining 6.2% above its 200-day moving average. Technical signals show neutral RSI of 50 and bearish MACD signal, explaining why TGTX maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$33.85
Potential Upside
46.2%
Whystock Fair Value$49.50
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Buy
Mean target$44.57+31.7%
Range$15.00 – $60.00
Fundamentals
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMV...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.01B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
13.58
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.75
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
9.33%
Volume
Today's trading volume
1.47M
Recent News
Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A Look At TG Therapeutics (TGTX) Valuation After Recent Share Price Momentum
Event context and recent stock move TG Therapeutics (TGTX) has caught investor attention recently as its share price closed at $35.33, with returns of 3% over the past day and about 17% over the past month. See our latest analysis for TG Therapeutics. The recent 17.5% 1 month share price return and 20.7% year to date share price return stand in contrast to a 7.8% decline in the 1 year total shareholder return. This suggests that momentum has picked up after a weaker patch. If TG Therapeutics...
TGTX Completes Enrollment in Phase III Study on Subcutaneous Briumvi
TG Therapeutics completes enrollment in a phase III study of subcutaneous Briumvi for treating RMS in adults, with data expected by late 2026 or early 2027.
TG Therapeutics concludes enrolment in Phase III Briumvi trial
The trial will compare the radiological, safety, and clinical outcomes of subcutaneous versus IV Briumvi.